This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Panel Backs Inhaled Insulin

A Food and Drug Administration advisory committee has voted to recommend Pfizer's (PFE - Get Report) Exubera, an inhaled insulin product, despite concerns about the drug's long-term effects, especially on people with lung disease.

The panel of endocrinologists voted 7-2 Thursday to recommend Exubera to treat both type 1 and type 2 diabetes. If approved, Exubera would be the first inhaled insulin product on the market.

The panel was split on whether to recommend the drug for diabetes patients who smoke, are exposed to cigarette smoke or have lung disease. Insulin absorption in those patients could vary significantly from those without lung disease and exposure to smoke. The FDA isn't required to act on the committee's recommendation. However, normally the agency does follow the advice of its panels.

While research indicates that the drug is as effective as currently available injectible insulin, the inhaled version comes with another set of side effects. According to Pfizer's safety and efficacy trials, next to hypoglycemia, or low-blood sugar (which also occurs with injected insulin), the most common side effects of Exubera were respiratory tract infections, cough and an inflammation called pharyngitis.

Exubera was co-developed with Nektar Therapeutics (NKTR - Get Report) and Sanofi-Aventis (SNY - Get Report).

Pfizer may submit additional safety data on Exubera to ease worries about long-term side effects. In safety trials, 821 patients were treated for more than two years and 153 were treated for more than three years, but only 15 patients were treated for more than seven years.

Something that's still unclear is whether different techniques in using the inhalation device lead to varied doses of Exubera being absorbed into the lungs. If so, doctors and patients could require time to learn to use the inhalation device properly, which could slow the drug's acceptance among diabetics and health professionals.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
NKTR $11.33 -1.30%
PFE $34.33 0.73%
SNY $51.43 0.27%
AAPL $128.73 -0.17%
FB $78.81 -0.23%

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs